Dr. Pasi A. Jänne MD, PhD, (Pasi_Janne@dfci.harvard.edu) is a translational thoracic medical oncologist at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. He is the director of the Lowe Center for Thoracic Oncology and the scientific co-director of the Belfer Center for Applied Cancer Sciences. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr. Jänne completed his internship and residency in medicine at Brigham and Women’s Hospital.
He completed fellowship training in 2001 at the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology. He earned a master’s degree in clinical investigation from Harvard University in 2002.
Dr. Jänne has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016), and the Finnish Academy of Science and Letters (2016). Dr. Jänne is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award and a member of the 2010 AACR Team Science Award.
Magda Bahcall, PhD, (Magda_Bahcall@dfci.harvard.edu) is the Jänne lab director. She oversees the design and execution of in vitro and in vivo target validation, proof of mechanism, and proof of concept studies, as well as collaborations with other Dana-Farber Center Institute and external partners. She provides managerial oversight for research and related activities, and staff recruitment. Her primary research interests are in the MET proto-oncogene, both as a driver and resistance promoter in NSCLC, and tumor heterogeneity as a factor in resistance development.
Jiaqi Li, BA, (Jiaqi_Li@dfci.harvard.edu) is the laboratory manager for Dr. Jänne’s research group and is responsible for all operations and logistics. He is also investigating the therapuetic benefits of MAPK pathway inhibitors in RAS mutant cancer cell lines.
Jennifer Largaespada, BA (Jennifer_Largaespada@dfci.harvard.edu) is the Executive Assistant to Dr. Jänne.